Search results for "Viral hepatitis."

showing 10 items of 102 documents

Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.

2016

Background & Aims: Life expectancy of patients with compensated hepatitis C virus (HCV) cirrhosis achieving sustained virologic response (SVR) is limited by liver events as compared to the general population. Thus, survival benefit of SVR remains to be measured. Methods: The study includes prospective surveillance data from three cohorts of Italian patients with compensated HCV cirrhosis who achieved SVR on an interferon-based (IFN) regimen, compared to simultaneously observed non-SVR, untreated and decompensated patients. Overall survival was calculated from the date of start of IFN to death. The number of deaths expected during the at-risk period was determined by applying age- and se…

AdultLiver CirrhosisMalemedicine.medical_specialtySustained Virologic ResponsePopulation03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansProspective StudieseducationSurvival analysisAgededucation.field_of_studyHepatologybusiness.industryMortality rateHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseSurgerySurvival RateRegimenStandardized mortality ratio030220 oncology & carcinogenesisRelative riskHCVFemale030211 gastroenterology & hepatologyInterferonsViral hepatitisbusiness
researchProduct

Autoreactive liver-infiltrating T cells in primary biliary cirrhosis recognize inner mitochondrial epitopes and the pyruvate dehydrogenase complex.

1993

Primary biliary cirrhosis (PBC) is characterized by lymphoid infiltrates in the portal tracts of the liver and the occurrence of antimitochondrial autoantibodies in serum directed against components of the pyruvate dehydrogenase complex and the other alpha-keto acid dehydrogenase complexes. These enzymes are located on the inner mitochondrial membrane. The destruction of the biliary tract in PBC is thought to be mediated by autoreactive liver-infiltrating T cells exerting cytotoxic activity or releasing certain lymphokines. In this study the reactivity of liver infiltrating T cells was shown to a bovine pyruvate dehydrogenase complex (PDH), a purified E2 subunit (PDH-E2) and a crude prepara…

AdultMaleAdolescentBiliary cirrhosisT-LymphocytesEnzyme-Linked Immunosorbent AssayMitochondria LiverPyruvate Dehydrogenase ComplexAutoimmune hepatitisEpitopesPrimary biliary cirrhosisCell MovementmedicineCytotoxic T cellHumansCells CulturedAgedAutoantibodiesHepatologybiologyLiver Cirrhosis BiliaryAntibodies MonoclonalMiddle Agedmedicine.diseasePyruvate dehydrogenase complexPhenotypeLiverImmunologybiology.proteinFemaleAntibodyViral hepatitisCD8Journal of hepatology
researchProduct

Autoantibodies against the human asialoglycoprotein receptor: Effects of therapy in autoimmune and virus-induced chronic active hepatitis

1993

The hepatic asialoglycoprotein receptor (ASGPR) was recently identified as a target antigen for both humoral and cellular immune response in inflammatory liver diseases. Thereby anti-ASGPR autoantibodies directed against human substrate were closely associated with autoimmune chronic active hepatitis. The present study compares the occurrence, titer and immunoglobulin classification of anti-human(h-)-ASGPR antibodies in 23 patients with newly diagnosed autoimmune chronic hepatitis before and after initiation of immunosuppressive therapy to 22 patients with autoimmune hepatitis in remission. Additionally, 1-year follow-up examinations of 42 patients with HBsAg-positive chronic hepatitis and …

AdultMaleAdolescentHepatitis Viral Humanmedicine.medical_treatmentAsialoglycoproteinsReceptors Cell SurfaceAsialoglycoprotein ReceptorAutoimmune hepatitisAutoimmune DiseasesInterferonImmune ToleranceHumansMedicineChildAgedAutoantibodiesHepatitis ChronicHepatitisHepatologybiologybusiness.industryAutoantibodyImmunotherapyMiddle Agedmedicine.diseaseTiterImmunologybiology.proteinFemaleImmunotherapyAntibodybusinessViral hepatitisFollow-Up Studiesmedicine.drugJournal of Hepatology
researchProduct

Can the serological status of anti-HBc alone be considered a sentinel marker for detection of occult HBV infection?

2008

Some individuals have “occult” infection with hepatitis B virus (HBV), defined as presence of HBV genome in the serum or liver tissue without HBV surface antigen (HBsAg) in the serum. The aim of this study was to investigate whether serum antibodies against HBV core antigen in isolation (“anti-HBc alone”) are a useful marker of “occult” HBV in patients with or without hepatitis C virus (HCV) infection. “Anti-HBc alone” was detected in the sera of 119/6,544 (1.8%) asymptomatic outpatients referred to the diagnostic laboratory for routine testing for viral hepatitis, 62/607 (10.2%) drug users, and 42/195 (21.5%) patients with hepatocellular carcinoma. Using three in-house nested-PCR amplifica…

AdultMaleHBV serologic markerHBsAgHepatitis B virusGenotypeHepatitis C virusHBV genotypemedicine.disease_causeSettore MED/42 - Igiene Generale E ApplicataPolymerase Chain ReactionSensitivity and Specificity‘‘occult’’ HBVSerologyOrthohepadnavirusVirologymedicinePrevalenceHumansSerologic TestsHCCAgedHepatitis B virusAged 80 and overbiologybusiness.industryvirus diseasesSequence Analysis DNAHepatitis C AntibodiesMiddle Agedbiology.organism_classificationmedicine.diseaseHepatitis BVirologyHepatitis B Core AntigensHepatitis Cdigestive system diseasesInfectious DiseasesHepadnaviridaeImmunologyDNA Viralanti-HBcFemaleViral diseasebusinessViral hepatitisSentinel Surveillance
researchProduct

Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins.

2002

Summary Background The course of viral hepatitis is thought to be affected by genetic host variability and, in particular, by genes of the major histocompatibility locus. Hepatitis A and B vaccination is a useful model to study the effect of host factors on the immune response to viral antigens. We aimed to assess the heritability of the HBsAg (anti-HBs) and anti-hepatitis A virus (anti-HAV) immune response and to estimate the effect of the HLA-DRB1 locus and other genetic loci unlinked to HLA. Methods We did an open prospective study and vaccinated 202 twin pairs with a combined recombinant HBsAg/inactivated hepatitis A vaccine. We measured antibodies to HBsAg and HAV and determined HLA-DR…

AdultMaleHBsAgAdolescentHepatitis A vaccineHuman leukocyte antigenBiologyHepatitis A AntibodiesmedicineHumansHepatitis B VaccinesHepatitis B AntibodiesAgedGeneticsHepatitis B Surface AntigensVaccinationvirus diseasesHepatitis AGeneral MedicineHLA-DR AntigensHeritabilityMiddle Agedmedicine.diseasebiology.organism_classificationdigestive system diseasesRecombinant ProteinsImmunity ActiveHepadnaviridaeImmunologybiology.proteinTwin Studies as TopicFemaleHepatitis A virusAntibodyViral hepatitisHLA-DRB1 ChainsLancet (London, England)
researchProduct

Familiar clustering and spreading of hepatitis delta virus infection

1985

The prevalence of hepatitis delta virus (HDV) infection was significantly higher among the relatives of 79 carriers of HBsAg with antibody to HDV (index cases) than among relatives of 111 carriers without serological evidence of HDV infection (controls). Antibody to HDV was found in 45 of the 80 (56%) carriers of HBsAg in families of index cases but only in 2 of 59 (3%) carriers in families of controls (P less than 0.0001). During follow-up new HDV infection developed in 31% of 13 susceptible carriers in families of index cases, but only in 1.2% of 162 susceptible carriers in families of controls (P less than 0.001). None of the family members previously unexposed to the hepatitis B virus h…

AdultMaleHBsAgvirusesmedicine.disease_causeVirusmedicineHumansHepatitis B virusHepatologybiologyInfantvirus diseasesbiochemical phenomena metabolism and nutritionHepatitis BHepatitis Bmedicine.diseaseHepatitis DVirologyHepatitis DChild PreschoolCarrier StateImmunologybiology.proteinFemaleViral diseaseAntibodyViral hepatitisFollow-Up Studies
researchProduct

Early neutralizing and glycoprotein B (gB)-specific antibody responses to human cytomegalovirus (HCMV) in immunocompetent individuals with distinct c…

2000

Abstract Background: Antibodies with functional anti-Human Cytomegalovirus (HCMV) activity are likely to be involved in preventing virus dissemination and thus may contribute to minimize the clinical manifestations of infection. Objectives: To investigate the role of humoral immunity in modulating the clinical expression of primary Human Cytomegalovirus (HCMV) infection in immunocompetent persons. Study design: Neutralizing (NA) and glycoprotein B (gB)-specific antibodies were quantitated in acute-phase and late-convalescence phase sera from 19 individuals who developed either HCMV mononucleosis (12) or oligosymptomatic hepatitis (seven). Results: The levels of NA in sera drawn early after …

AdultMaleHuman cytomegalovirusAdolescentHepatitis Viral HumanMononucleosisvirusesAntibody AffinityCongenital cytomegalovirus infectionBiologyAntibodies ViralViral Envelope ProteinsNeutralization TestsVirologymedicineHumansAvidityInfectious MononucleosisChildmedicine.diseaseVirologyInfectious DiseasesChild PreschoolImmunoglobulin GCytomegalovirus InfectionsDNA ViralHumoral immunityImmunologybiology.proteinFemaleAntibodyViral hepatitisImmunocompetenceViral loadJournal of Clinical Virology
researchProduct

Impact of HBV genotypes A and D genetic variability on infection evolution

2015

HBV is characterized by a high genetic variability, which is the basis of its classification into eight genotypes (A-H). HBV infection is associated with different outcomes, from self-limiting acute hepatitis to active chronic hepatitis, asymptomatic carriage, and occult infection. The aim of this study was to analyze the genetic variability of HBV genotypes A and D isolates from 79 cases of self-limiting acute hepatitis and chronic hepatitis, in order to identify HBV variants associated with resolution or chronicity of acute HBV infection. The entire preS-S sequence and a fragment of 346 bp of the preC-C region, containing Enhancer II and Basal Core Promoter sequences, were analyzed. A phy…

AdultMaleMicrobiology (medical)Hepatitis B virusSettore MED/07 - Microbiologia E Microbiologia ClinicaGenotypeAcute hepatitis BBiologymedicine.disease_causeMicrobiologyLiver diseaseViral ProteinspreC/C mutationGeneticImmune-escape mutationGenetic variationGenotypeGeneticsmedicineHumansViral ProteinGenetic variabilityMolecular BiologyEcology Evolution Behavior and SystematicsPhylogenyAgedHepatitis B virusPolymorphism GeneticpreS/S mutationGenetic VariationHepatitis B viruHepatitis BMiddle Agedmedicine.diseaseHepatitis BVirologyBiological EvolutionEcology Evolution Behavior and SystematicInfectious DiseasesAmino Acid SubstitutionViral evolutionImmunologyMutationFemaleViral hepatitisHuman
researchProduct

Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up.

1998

Acute infection with hepatitis C virus (HCV) develops into a chronic hepatitis in about 50-70% of patients. Treatment of these patients with interferon-alpha (IFN-alpha) results in a sustained long-term response in only 15-20% but causes numerous unwanted side-effects in a higher percentage of patients. The aim of our study was to define host or viral parameters that would allow identification of responders and non-responders to IFN-alpha prior to the onset of treatment. We studied a group of 87 patients suffering from chronic hepatitis C who were treated with IFN-alpha. After long-term follow-up, 18 patients (21%) showed a sustained response to IFN-alpha therapy (normalization of serum tra…

AdultMaleNecrosisGenotypeHepatitis C virusAlpha interferonInflammationHepacivirusmedicine.disease_causeAntiviral AgentsFibrosisVirologyGenotypemedicineHumansViremiaHepatologymedicine.diagnostic_testbusiness.industryTumor Necrosis Factor-alphaInterferon-alphaHLA-DR AntigensHepatitis C ChronicMiddle AgedViral Loadmedicine.diseaseInfectious DiseasesTreatment OutcomeLiver biopsyImmunologyRNA ViralFemalemedicine.symptombusinessViral hepatitisFollow-Up StudiesJournal of viral hepatitis
researchProduct

LOW-DOSE INTERLEUKIN-2 INDUCES SYSTEMIC IMMUNE RESPONSES AGAINST HBsAg IN IMMUNODEFICIENT NON-RESPONDERS TO HEPATITIS B VACCINATION

1989

Abstract A metabolic monocyte defect appears to correlate with non-responsiveness to hepatitis B vaccine in many patients on haemodialysis. This defect prevents production of interleukin-2 during T-cell activation after antigen contact. Receptors for interleukin-2 are, however, expressed in greater numbers than in healthy subjects or uraemic responders to hepatitis B vaccination. In this study, ten uraemic patients, previous non-responders to vaccination against hepatitis B, were revaccinated with the same vaccine combined with one intramuscular injection (2·5 × 10 5 U) of natural human interleukin-2. Systemic production of antibodies against hepatitis B surface antigen was initiated in tho…

AdultMaleViral Hepatitis VaccinesInterleukin 2HBsAgHepatitis B vaccinePilot ProjectsImmunoenzyme TechniquesImmune systemAntigenmedicineHumansHepatitis B VaccinesAgedUremiaHepatitis B Surface Antigensbiologybusiness.industryImmunologic Deficiency SyndromesReceptors Interleukin-2General MedicineMiddle AgedHepatitis Bmedicine.diseaseVirologyVaccinationAntibody FormationImmunologybiology.proteinInterleukin-2FemaleAntibodybusinessmedicine.drugThe Lancet
researchProduct